IDiyas

For the Inventor, By the Inventor

Munich, Germany

Claudio Sustmann

USPTO Granted Patents = 12 

Average Co-Inventor Count = 8.3

ph-index = 4

Forward Citations = 47(Granted Patents)


Company Filing History:

goldMedal10 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents
silverMedal1 out of 2 
 
Ludwig-Maximillians-Universität München
 patents
bronzeMedal2 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...
12 patents (USPTO):
1. 11993642 - Trivalent, bispecific antibodies (2024-05-28),
2. 11787873 - Bispecific HER2 antibodies and methods of use (2023-10-17),
3. 11732052 - Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine (2023-08-22),
4. 11547748 - Adoptive t-cell therapy (2023-01-10),
5. 10808038 - HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2 (2020-10-20),
6. 10793621 - Nucleic acid encoding dual Fc antigen binding proteins (2020-10-06),
7. 10633451 - Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine (2020-04-28),
8. 10611825 - Monovalent antigen binding proteins (2020-04-07),
9. 10584178 - Bispecific HER2 antibodies and methods of use (2020-03-10),
10. 10434184 - Anti-TPBG antibodies and methods of use (2019-10-08),
11. 9982036 - Dual FC antigen binding proteins (2018-05-29),
12. 9890204 - Trivalent, bispecific antibodies (2018-02-13),

Title: Claudio Sustmann: A Pioneer in Bispecific Antibody Innovations

Introduction

Claudio Sustmann is a distinguished inventor based in Munich, Germany, known for his groundbreaking work in the field of biotechnology, particularly in the development of bispecific antibodies. With a remarkable portfolio of 12 patents, Sustmann has significantly contributed to the advancement of therapeutic solutions for various diseases.

Latest Patents

Among his latest innovations, Sustmann has developed trivalent, bispecific antibodies, which relate to methods for their production, pharmaceutical compositions containing these antibodies, and their various uses. Another notable patent involves bispecific HER2 antibodies, which includes novel HER2 antibody variants, their production methods, and applications in pharmaceutical compositions.

Career Highlights

Sustmann has had an impactful career, having worked with prominent organizations such as Hoffmann-La Roche Inc. His contributions to the field of biotechnology have solidified his reputation as a leading inventor in antibody therapy.

Collaborations

Throughout his career, Sustmann has collaborated with notable professionals, including Christian Klein and Wolfgang Schaefer. These partnerships have enhanced his research and development efforts, leading to innovative solutions in the field.

Conclusion

Claudio Sustmann stands out as a key figure in the realm of bispecific antibodies. His patents not only showcase his inventive prowess but also hold promise for future advancements in medical treatments, demonstrating the ever-evolving landscape of biotechnological innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…